Clene Says CNM-Au8 Shows Statistically Significant Difference In Plasma Neurofilament Light Levels In HEALEY ALS Platform Trial
Portfolio Pulse from Benzinga Newsdesk
Clene announced that CNM-Au8 treatment showed a statistically significant reduction in plasma neurofilament light chain levels compared to placebo in the HEALEY ALS Platform Trial. The company plans to discuss the results at an upcoming FDA meeting to accelerate the path toward approval.
June 15, 2023 | 8:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clene's CNM-Au8 treatment demonstrated positive results in the HEALEY ALS trial, which may lead to accelerated FDA approval.
The positive results from the HEALEY ALS trial indicate that Clene's CNM-Au8 treatment is effective in reducing plasma neurofilament light chain levels. This may lead to accelerated FDA approval, which would be a significant milestone for the company and could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100